Rheumatoid Arthritis

      Fibromyalgianess Glucocorticoid Persistence in RA Patients: Dr. Sheila Reyes
      3 years 11 months ago
      ARIAA Study - Abatacept Reverses ACPA+ Subclinical Arthritis: Dr. Jack Cush
      3 years 11 months ago
      RT @DrMiniDey: Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #Alz

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #AlzheimersDisease & related #dementia in RA pts. 👉~1300 patients 👉Among CVD conditions, #stroke & #CHF assoc w/ the risk of #dementia #ACR21 Abs#0284 @RheumNow https://t.co/N3x2ZtBFGe https://t.co/kFyf3A0gha
      RT @DrPetryna: Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%rep

      Olga Petryna DrPetryna

      3 years 11 months ago
      Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?
      Feet, foot
      Pre-clinical RA: starting off the wrong foot
      3 years 11 months ago
      Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
      RT @MeralElRamahiMD: #ACR21 Abst#0284
      My 56 yo ♀RA pt expressed concern for developing dementia last wk. This study he

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 11 months ago
      #ACR21 Abst#0284 My 56 yo ♀RA pt expressed concern for developing dementia last wk. This study helps recognize her RF beyond aging: ➡️ Large joint swelling (HR 2.2) ➡️ CVD (HR 2.4): stroke (HR 3.2) + chronic HF (HR 1.8) ➡️ DM (HR 1.6) #ACRBest @Rheumnow https://t.co/wsZnaLwSmD
      RT @AurelieRheumo: Provocative study in pre-RA. SC Abatacept in patients with pre-clinical RA can:
      -improvement MRI infl

      Aurelie Najm AurelieRheumo

      3 years 11 months ago
      Provocative study in pre-RA. SC Abatacept in patients with pre-clinical RA can: -improvement MRI inflammation -⬇️evolution to clinical RA at 6 months -No new safety signal Yes, but we need longer term follow-up and an estimation of NNT. #OP0505 @Rheumnow #ACR2021 https://t.co/2P1Yk3IyeR
      RT @DrMiniDey: Do RA autoantibodies incr the risk of MACE?

      In study of ~2000 pts, ⬆️ concentrations of RA-related a

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Do RA autoantibodies incr the risk of MACE? In study of ~2000 pts, ⬆️ concentrations of RA-related autoantibodies assoc. w/ MACE and/or CVD-mortality. Autoantibodies may therefore directly contribute to excess CVD risk in RA... Abs#0269 #ACR21 @RheumNow https://t.co/ju3YCRonJt https://t.co/UcOMsYxVMP
      RT @AkhilSoodMD: Abs 0463 #ACR21 @RheumNow
      Park & colleagues compared treatment persistence across abatacept, TNFi,

      Akhil Sood MD AkhilSoodMD

      3 years 11 months ago
      Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
      RT @AurelieRheumo: Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients
      with clinically suspect arthralgia

      Aurelie Najm AurelieRheumo

      3 years 11 months ago
      Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients with clinically suspect arthralgia undergoing MRI: -23% intermetatarsal bursitis > ACPA + 56% vs. 19% -higher risk or RA HR 3.3. Would we find the same results w/ US? #OP0468 @RheumNow #ACR2021 https://t.co/VkzUu93qGq https://t.co/GGw7UgdPVR
      RT @RHEUMarampa: Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin susp

      sheila RHEUMarampa

      3 years 11 months ago
      Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin suspect arthralgia(CSA) pts; predicted clinical arthritis in ACPA+; ⬆ frequent w/ synovitis & tenosynovitis Addtl tool for early RA dx? @RheumNow #ACR21 abs0468 #ACRBest https://t.co/bcUuy8bHLJ
      RT @ericdeinmd: #ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis
      ⭐️ ACPA + arthralgia + MRI inflamm

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis ⭐️ ACPA + arthralgia + MRI inflammation 🔥 ⭐️ ⬇️ MRI inflam (primary) and ⬇️ progression to arthritis (secondary) ▶️ Many patients likely early RA, would still rec starting MTX 1st https://t.co/4aREvqlpUI @Rheumnow https://t.co/vqRgsd75Il
      RT @MeralElRamahiMD: #ACR21 Abst#0293:
      Lung involvement in 67 sero+ RA pts assoc w/:
      ⭐︎ SSc-specific ab
      ➡️ RP1

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 11 months ago
      #ACR21 Abst#0293: Lung involvement in 67 sero+ RA pts assoc w/: ⭐︎ SSc-specific ab ➡️ RP155, Th/To, fibrillarin, NOR90 in ILD group ➡️ Ku, Pm/Scl100, CENP-A/B in non-ILD group ⭐︎ older age, ⚦ sex, heavy 🚬 ⭐︎ ↑ WBC, CRP, RF #ACRBest @Rheumnow https://t.co/Yo4jRKqvfV https://t.co/l5gbKoZBkm
      RT @RichardPAConway: ARIAA study of abatacept in pre-RA. Abatacept ⬇️MRI inflammation and reduces progression to RA.

      Richard Conway RichardPAConway

      3 years 11 months ago
      ARIAA study of abatacept in pre-RA. Abatacept ⬇️MRI inflammation and reduces progression to RA. Of course it does. Like all these studies, really not sure what this is telling us. Abstr#0455 #ACR21 @RheumNow https://t.co/yNVVZFBWDq
      RT @synovialjoints: Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%)

      Dr. Antoni Chan synovialjoints

      3 years 11 months ago
      Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE

      Catch up on Conference Podcasts

      ×